Literature DB >> 24352641

Managing breast cancers with low estrogen receptor and HER2 by drugging both.

Todd W Miller1.   

Abstract

Low estrogen receptor (ER) levels in breast tumors are associated with poorer response to antiestrogen therapy. Finn and colleagues identify low ER levels as a biomarker predicting benefit from the addition of the EGFR/HER2 dual inhibitor lapatinib to an antiestrogen treatment regimen in patients with metastatic ER(+)/HER2(-) breast cancer. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24352641      PMCID： PMC3946528          DOI： 10.1158/1078-0432.CCR-13-2994

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Authors:  Todd W Miller; Justin M Balko; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

2.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Authors:  Wenle Xia; Sarah Bacus; Priti Hegde; Intisar Husain; Jay Strum; Leihua Liu; Georgina Paulazzo; Ljuba Lyass; Patricia Trusk; Jason Hill; Jennifer Harris; Neil L Spector
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

3.  Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

Authors:  Suleiman Massarweh; C Kent Osborne; Shou Jiang; Alan E Wakeling; Mothaffar Rimawi; Syed K Mohsin; Susan Hilsenbeck; Rachel Schiff
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

4.  Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.

Authors:  Massimo Cristofanilli; Vicente Valero; Aroop Mangalik; Melanie Royce; Ian Rabinowitz; Francis P Arena; Joan F Kroener; Elizabeth Curcio; Claire Watkins; Sarah Bacus; Elsa M Cora; Elizabeth Anderson; Patrick J Magill
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

5.  Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

Authors:  C Kent Osborne; Patrick Neven; Luc Y Dirix; John R Mackey; Jean Robert; Craig Underhill; Rachel Schiff; Carolina Gutierrez; Ilenia Migliaccio; Valsamo K Anagnostou; David L Rimm; Patrick Magill; Mark Sellers
Journal:  Clin Cancer Res       Date:  2011-01-10       Impact factor: 12.531

6.  The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.

Authors:  A D Hartkopf; M Banys; F Meier-Stiegen; M Hahn; C Röhm; J Hoffmann; G Helms; F A Taran; M Wallwiener; C Walter; H Neubauer; D Wallwiener; T Fehm
Journal:  Breast Cancer Res Treat       Date:  2013-03-15       Impact factor: 4.872

7.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Authors:  Stephen Johnston; John Pippen; Xavier Pivot; Mikhail Lichinitser; Saeed Sadeghi; Veronique Dieras; Henry Leonidas Gomez; Gilles Romieu; Alexey Manikhas; M John Kennedy; Michael F Press; Julie Maltzman; Allison Florance; Lisa O'Rourke; Cristina Oliva; Steven Stein; Mark Pegram
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

8.  Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Authors:  Mitch Dowsett; Craig Allred; Jill Knox; Emma Quinn; Janine Salter; Chris Wale; Jack Cuzick; Joan Houghton; Norman Williams; Elizabeth Mallon; Hugh Bishop; Ian Ellis; Denis Larsimont; Hironobu Sasano; Pauline Carder; Antonio Llombart Cussac; Fiona Knox; Valerie Speirs; John Forbes; Aman Buzdar
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

9.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Authors:  Thomas Bachelot; Céline Bourgier; Claire Cropet; Isabelle Ray-Coquard; Jean-Marc Ferrero; Gilles Freyer; Sophie Abadie-Lacourtoisie; Jean-Christophe Eymard; Marc Debled; Dominique Spaëth; Eric Legouffe; Djelila Allouache; Claude El Kouri; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544

10.  Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.

Authors:  Antoni Hurtado; Kelly A Holmes; Timothy R Geistlinger; Iain R Hutcheson; Robert I Nicholson; Myles Brown; Jie Jiang; William J Howat; Simak Ali; Jason S Carroll
Journal:  Nature       Date:  2008-11-12       Impact factor: 49.962
View more
  1 in total

1.  Identification and validation of a prognostic risk model based on caveolin family genes for breast cancer.

Authors:  Qiang Tang; Shurui Wang; Ziyang Di; Huimin Li; Kailiang Xu; Xin Hu; Maojun Di
Journal:  Front Cell Dev Biol       Date:  2022-09-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.